The New Products Committee is in charge of detecting opportunities for developing products. This Committee performs a double analysis process. On the one hand, they identify the medical areas with specific needs and, on the other hand, they establish the feasibility of the project.

Once a need in a specific medical area is identified, a study is conducted to assess the technical complexity of the R+D, the patents, the development of the chemical process and, finally, the Galenic development. Meanwhile, a group of experts assess, in general terms, the final feasibility of the project.

Whether we are dealing with a new product, or launching a new generic product, the R+D team develops a research process that, in the end, will make it possible to make the drug available for patients. After a molecule validation process, the R+D Chemical Department conducts the necessary safety tests in the pilot plant located Sant Fost de Campsentelles (Barcelona).

The Production Department in the Chemical Plant (Urquima) is responsible for scaling the product and assessing the commercial batches, so that it can then be manufactured in the Pilot Plant or in the Industrial Plant, always depending on the specific project needs.

The Pharmacotechnical department is in charge of developing the formula for the new product. If dealing with a generic product, through its development, we obtain the formula of a bioequivalent product. When the project is based on a new product, the formula will make it possible to conduct the industrial scaling for launching. Finally, the Pilot Plant tests the product using the established controls and assays so that then the scaling can be done in the Industrial Plant.

Once we have confirmed that the new product can be marketed, the Registers Department starts the legal registration procedure. Also, this guarantees that all the necessary technical requirements are met.

The product made in Urquima reaches the Pharmaceutical Plant to be transformed into the finished product. The Logistics Department receives and stores the Urquima raw material, while the Quality Control Department carries out the corresponding analyses. Then the first stage of the manufacturing process, which will convert the active ingredient into a semi-finished product, is developed. Finally, the tablets, coated tablets, effervescent tablets, coated pills, capsules, creams and ointments are manufactured in the plant.

Once the semi-finished product is made, the product conditioner is developed. In the pharmaceutical plant, solid shapes are made in different formats (blisters, sachets, bottles, aluminum tubes, etc.) Throughout the manufacturing process, controls are run to check the product quality.

The Quality Control Department checks that the product complies with the quality standard required by the sector, so as to proceed with releasing the product. The Logistics Centre in Palau-solità i Plegamans (Barcelona) stores the finished product and prepares it for transport.

Once the process is complete, product marketing begins. Through our Clients, Partners or Licensees, the Uriach Group prepares launching the product onto the market. Through pharmacies and hospitals we make sure the product reaches all patients.